These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22837197)

  • 21. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
    Di Mario G; Soprana E; Gubinelli F; Panigada M; Facchini M; Fabiani C; Garulli B; Basileo M; Cassone A; Siccardi A; Donatelli I; Castrucci MR
    Pathog Glob Health; 2017 Mar; 111(2):69-75. PubMed ID: 28081672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
    Hossain MJ; Bourgeois M; Quan FS; Lipatov AS; Song JM; Chen LM; Compans RW; York I; Kang SM; Donis RO
    Clin Vaccine Immunol; 2011 Dec; 18(12):2010-7. PubMed ID: 22030367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.
    Prabakaran M; Meng T; He F; Yunrui T; Qiang J; Lin RT; Kwang J
    Clin Vaccine Immunol; 2011 Sep; 18(9):1582-5. PubMed ID: 21752948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities.
    Hodgins B; Pillet S; Landry N; Ward BJ
    PLoS One; 2019; 14(1):e0210009. PubMed ID: 30629622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.
    Wegmann F; Moghaddam AE; Schiffner T; Gartlan KH; Powell TJ; Russell RA; Baart M; Carrow EW; Sattentau QJ
    Clin Vaccine Immunol; 2015 Sep; 22(9):1004-12. PubMed ID: 26135973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programming the magnitude and persistence of antibody responses with innate immunity.
    Kasturi SP; Skountzou I; Albrecht RA; Koutsonanos D; Hua T; Nakaya HI; Ravindran R; Stewart S; Alam M; Kwissa M; Villinger F; Murthy N; Steel J; Jacob J; Hogan RJ; García-Sastre A; Compans R; Pulendran B
    Nature; 2011 Feb; 470(7335):543-7. PubMed ID: 21350488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll-like receptor 7 controls the anti-retroviral germinal center response.
    Browne EP
    PLoS Pathog; 2011 Oct; 7(10):e1002293. PubMed ID: 21998589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
    Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
    Front Immunol; 2018; 9():2619. PubMed ID: 30515151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
    Cho A; Wrammert J
    Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production.
    Li C; To KKW; Zhang AJX; Lee ACY; Zhu H; Mak WWN; Hung IFN; Yuen KY
    Front Immunol; 2018; 9():2370. PubMed ID: 30369932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
    Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
    J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009.
    Gauger PC; Loving CL; Lager KM; Janke BH; Kehrli ME; Roth JA; Vincent AL
    Viral Immunol; 2013 Oct; 26(5):314-21. PubMed ID: 24033080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses.
    Heer AK; Shamshiev A; Donda A; Uematsu S; Akira S; Kopf M; Marsland BJ
    J Immunol; 2007 Feb; 178(4):2182-91. PubMed ID: 17277123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.